{"id":"W1998198982","doi":"10.1016/j.ygyno.2006.10.006","title":"Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel—ANZGOG 02-01","year":2006,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Health Canada; Pfizer Canada; Pfizer","keywords":"Medicine; Docetaxel; Paclitaxel; Neutropenia; Internal medicine; Chemotherapy; Ovarian cancer; Oncology; Toxicity; Cancer; Surgery","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004343562,0.0003969586,0.001406,0.0001620444,0.0002192592,0.0000130692,0.0001707949,0.0004615452,0.001053921],"category_scores_gemma":[0.0003728738,0.0002818374,0.0002733728,0.0002216858,0.0002452153,0.00009088618,0.00006510998,0.0002415501,0.000009303396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001046539,"about_ca_system_score_gemma":0.0009583784,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006161022,"about_ca_topic_score_gemma":0.001273329,"domain_scores_codex":[0.9971815,0.0001875432,0.0008826225,0.0007316927,0.0003096739,0.0007070223],"domain_scores_gemma":[0.9972978,0.000810043,0.0007501473,0.0005137111,0.0004291892,0.0001991442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2630903,0.1218746,0.2012807,0.0005096028,0.002512777,0.0002916699,0.001047452,0.0001154409,0.0002400906,0.002257216,0.1286844,0.2780958],"study_design_scores_gemma":[0.5480865,0.1737327,0.1373144,0.0001600966,0.00173371,0.000008599528,0.0001020679,0.00006623397,0.0004378555,0.0008358319,0.137112,0.0004099182],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9722339,0.0004789277,0.00008848878,0.007811774,0.0009520365,0.006940006,0.0003288829,0.00007939315,0.0110866],"genre_scores_gemma":[0.9882144,0.0003110948,0.00374079,0.0007893136,0.0005238092,0.003246969,0.0003554209,0.00005249082,0.002765652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2849962,"threshold_uncertainty_score":0.9999634,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02246963538514211,"score_gpt":0.3245821224454167,"score_spread":0.3021124870602745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}